Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata

• Status: Completed
• Trial end date: 2015-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Alopecia areata (AA) is an autoimmune disease that involves the hair follicles. Topical corticosteroids are the established agents for treating this disorder. There are several case reports and case series which have demonstrated the efficacy of topical prostaglandins. The two agents have not been compared head-to-head in the published literature. The investigators attempt to compare the efficacy and safety of topical betamethasone and topical latanoprost in the treatment of localised alopecia areata.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Postgraduate Institute of Medical Education and Research
• Treatments: Betamethasone; Betamethasone benzoate; Betamethasone sodium phosphate; Betamethasone Valerate; Betamethasone-17,21-dipropionate; Latanoprost

Criteria

Inclusion Criteria:

• • Cases of AA involving scalp and beard area, having 5 or less patches in all, involving less than 40% area

• Stable disease without appearance of new patch or increase in size of existing patch for at least 15 days

Exclusion Criteria:

• • Pregnant and lactating women

• Patients on topical treatment for alopecia in the past fifteen days or on systemic treatment for alopecia in the past one month

• Presence of any contraindication for topical corticosteroids (local skin infections, skin atrophy) or latanoprost (pregnancy, lactation and dermatitis)

• Any other coexisting hair disorder (viz., trichotillomania, androgenetic alopecia, telogen effluvium)

• Extensive disease i.e. >5 patches of AA or area involving >40% area / alopecia totalis/ alopecia universalis/ ophiasis